Bluejay Diagnostics completes enrollment of 750 patients in SYMON-II sepsis study ahead of schedule

Bluejay Diagnostics, Inc.

Enrolled 750 patients ahead of plan in pivotal SYMON-II study evaluating Symphony IL-6 for early sepsis mortality risk assessment.
Preliminary observations indicate an approximately 17% 28-day mortality rate, providing a robust clinical dataset.
Study enrolled patients across leading U.S. healthcare institutions; results to support planned 510(k) submission to FDA.
Company expects to complete data cleaning, statistical analysis, and clinical reporting over the coming months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.